CooperVision: SightGlass Vision Diffusion Optics Technology Demonstrates Significant Reduction in Myopia Progression

Wednesday, October 6 2021 | 11 h 27 min | News, Press Release

CooperVision’s SightGlass Vision Business has revealed two-year clinical study data for its Diffusion Optics Technology^™, which is specifically designed to slow the progression of myopia in children. After two years, children who wore their Diffusion Optics Technology^™-enabled spectacles full time, including not removing them for near vision activities, progressed on average one-half diopter less than those wearing the control spectacles—a reduction of 59%.

The news was presented during a launch event in the Netherlands yesterday, timed with the world’s first commercial launch of the technology. The product will be available from CooperVision to eye care professionals in the Netherlands beginning this month. EssilorLuxottica, which will also introduce the spectacle lenses with Diffusion Optics Technology^™, participated as well.

The CYPRESS clinical study enrolled, randomized, and dispensed the lenses to 256 eligible children across 14 clinical trial sites in the United States and Canada. At the time of enrollment, subjects were 6 to 10 years old having myopia between -0.75 D and -4.50 D.

After two years of wear, 85% of children wearing the innovative spectacle lenses showed less than one diopter of myopia progression. Moreover, the study also showed that 41% of the children wearing spectacle lenses with Diffusion Optics Technology^™ showed no clinically meaningful progression in refractive error after two years versus only 17% in the control group.

Distance visual acuity with lenses incorporating Diffusion Optics Technology^™ was on average better than 6/6 (20/20) at each visit and similar to single vision spectacle lenses at all visits from dispensing through the 24-month visit. In the trial, children on average wore both the test lenses and standard single vision spectacle lenses more than 12 hours each day over a 24-month period, suggesting that children readily adapted to the Diffusion Optics Technology^™. The CYPRESS trial is now continuing into its third year.

“Our team has been singularly focused on advancing medical science to not only correct children’s vision, but also to help slow the progression of myopia. Applying our Diffusion Optics Technology^™ to spectacle lenses makes myopia management straightforward to integrate within eye care practices and easy to become part of children’s everyday lives,”⁸ said Joe Rappon, OD, MS, FAAO, chief medical officer for SightGlass Vision.

Spectacle lenses incorporating SightGlass Vision^™ Diffusion Optics Technology™ already hold a CE Mark declaration to help slow the progression of myopia.

Earlier this year, CooperCompanies and EssilorLuxottica announced their intent to form a joint venture to accelerate the commercialization of technologies from SightGlass Vision.

Click HERE for the full press release.